Selecting the optimal solid form of an API during early drug development can mitigate the risk of failure later in development. This can be achieved through polymorph, salt and cocrystal screening.
Our general approach to screening is underpinned by three sequential phases:
- Phase 1: Comprehensive solid-state characterization and understanding of the material supplied
- Phase 2: Generation of solids polymorphs/salts/cocrystals followed by basic characterization and evaluation of the ‘hits’
- Phase 3: Scale-up of the relevant hits followed by full characterization and recommendations regarding the most suitable form for further development.

